349 related articles for article (PubMed ID: 30367935)
1. β-Casein micelles for oral delivery of SN-38 and elacridar to overcome BCRP-mediated multidrug resistance in gastric cancer.
Bar-Zeev M; Kelmansky D; Assaraf YG; Livney YD
Eur J Pharm Biopharm; 2018 Dec; 133():240-249. PubMed ID: 30367935
[TBL] [Abstract][Full Text] [Related]
2. β-casein nanovehicles for oral delivery of chemotherapeutic Drug combinations overcoming P-glycoprotein-mediated multidrug resistance in human gastric cancer cells.
Bar-Zeev M; Assaraf YG; Livney YD
Oncotarget; 2016 Apr; 7(17):23322-34. PubMed ID: 26989076
[TBL] [Abstract][Full Text] [Related]
3. Long-circulating PEG-PE micelles co-loaded with paclitaxel and elacridar (GG918) overcome multidrug resistance.
Sarisozen C; Vural I; Levchenko T; Hincal AA; Torchilin VP
Drug Deliv; 2012 Nov; 19(8):363-70. PubMed ID: 23030458
[TBL] [Abstract][Full Text] [Related]
4. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
[TBL] [Abstract][Full Text] [Related]
5. The Pyrazolo[3,4-d]pyrimidine Derivative, SCO-201, Reverses Multidrug Resistance Mediated by ABCG2/BCRP.
Ambjørner SEB; Wiese M; Köhler SC; Svindt J; Lund XL; Gajhede M; Saaby L; Brodin B; Rump S; Weigt H; Brünner N; Stenvang J
Cells; 2020 Mar; 9(3):. PubMed ID: 32143347
[TBL] [Abstract][Full Text] [Related]
6. 5-Oxo-hexahydroquinoline derivatives as modulators of P-gp, MRP1 and BCRP transporters to overcome multidrug resistance in cancer cells.
Ranjbar S; Khonkarn R; Moreno A; Baubichon-Cortay H; Miri R; Khoshneviszadeh M; Saso L; Edraki N; Falson P; Firuzi O
Toxicol Appl Pharmacol; 2019 Jan; 362():136-149. PubMed ID: 30391378
[TBL] [Abstract][Full Text] [Related]
7. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.
Dei S; Braconi L; Trezza A; Menicatti M; Contino M; Coronnello M; Chiaramonte N; Manetti D; Perrone MG; Romanelli MN; Udomtanakunchai C; Colabufo NA; Bartolucci G; Spiga O; Salerno M; Teodori E
Eur J Med Chem; 2019 Jun; 172():71-94. PubMed ID: 30947123
[TBL] [Abstract][Full Text] [Related]
8. The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer.
Zhang L; Li Y; Wang Q; Chen Z; Li X; Wu Z; Hu C; Liao D; Zhang W; Chen ZS
Mol Cancer; 2020 Jan; 19(1):10. PubMed ID: 31952518
[TBL] [Abstract][Full Text] [Related]
9. Structure-Based Discovery of Pyrimidine Aminobenzene Derivatives as Potent Oral Reversal Agents against P-gp- and BCRP-Mediated Multidrug Resistance.
Qiu Q; Zou F; Li H; Shi W; Zhou D; Zhang P; Li T; Yin Z; Cai Z; Jiang Y; Huang W; Qian H
J Med Chem; 2021 May; 64(9):6179-6197. PubMed ID: 33938746
[TBL] [Abstract][Full Text] [Related]
10. Chemosensitivity determinants of irinotecan hydrochloride in hepatocellular carcinoma cell lines.
Takahata T; Ookawa K; Suto K; Tanaka M; Yano H; Nakashima O; Kojiro M; Tamura Y; Tateishi T; Sakata Y; Fukuda S
Basic Clin Pharmacol Toxicol; 2008 Apr; 102(4):399-407. PubMed ID: 18248513
[TBL] [Abstract][Full Text] [Related]
11. Broad blocking of MDR efflux pumps by acetylshikonin and acetoxyisovalerylshikonin to generate hypersensitive phenotype of malignant carcinoma cells.
Mirzaei SA; Reiisi S; Ghiasi Tabari P; Shekari A; Aliakbari F; Azadfallah E; Elahian F
Sci Rep; 2018 Feb; 8(1):3446. PubMed ID: 29472576
[TBL] [Abstract][Full Text] [Related]
12. β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function.
Teng YN; Sheu MJ; Hsieh YW; Wang RY; Chiang YC; Hung CC
Phytomedicine; 2016 Mar; 23(3):316-23. PubMed ID: 26969385
[TBL] [Abstract][Full Text] [Related]
13. Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein.
Brooks TA; Minderman H; O'Loughlin KL; Pera P; Ojima I; Baer MR; Bernacki RJ
Mol Cancer Ther; 2003 Nov; 2(11):1195-205. PubMed ID: 14617793
[TBL] [Abstract][Full Text] [Related]
14. Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
Li XQ; Wang L; Lei Y; Hu T; Zhang FL; Cho CH; To KK
Eur J Med Chem; 2015 Aug; 101():560-72. PubMed ID: 26197160
[TBL] [Abstract][Full Text] [Related]
15. Beta-casein-based nanovehicles for oral delivery of chemotherapeutic drugs: drug-protein interactions and mitoxantrone loading capacity.
Shapira A; Markman G; Assaraf YG; Livney YD
Nanomedicine; 2010 Aug; 6(4):547-55. PubMed ID: 20100598
[TBL] [Abstract][Full Text] [Related]
16. Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer.
Zhang YK; Wang YJ; Lei ZN; Zhang GN; Zhang XY; Wang DS; Al-Rihani SB; Shukla S; Ambudkar SV; Kaddoumi A; Shi Z; Chen ZS
Cancer Lett; 2019 Feb; 442():104-112. PubMed ID: 30392788
[TBL] [Abstract][Full Text] [Related]
17. Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability.
Sane R; Mittapalli RK; Elmquist WF
J Pharm Sci; 2013 Apr; 102(4):1343-54. PubMed ID: 23334925
[TBL] [Abstract][Full Text] [Related]
18. Identification of GAS1 as an epirubicin resistance-related gene in human gastric cancer cells with a partially randomized small interfering RNA library.
Zhao L; Pan Y; Gang Y; Wang H; Jin H; Tie J; Xia L; Zhang Y; He L; Yao L; Qiao T; Li T; Liu Z; Fan D
J Biol Chem; 2009 Sep; 284(39):26273-85. PubMed ID: 19638344
[TBL] [Abstract][Full Text] [Related]
19. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.
To KKW; Wu X; Yin C; Chai S; Yao S; Kadioglu O; Efferth T; Ye Y; Lin G
J Ethnopharmacol; 2017 May; 203():110-119. PubMed ID: 28363522
[TBL] [Abstract][Full Text] [Related]
20. Optimization of dose and route of administration of the P-glycoprotein inhibitor, valspodar (PSC-833) and the P-glycoprotein and breast cancer resistance protein dual-inhibitor, elacridar (GF120918) as dual infusion in rats.
Rowbottom C; Pietrasiewicz A; Tuczewycz T; Grater R; Qiu D; Kapadnis S; Trapa P
Pharmacol Res Perspect; 2021 Apr; 9(2):e00740. PubMed ID: 33660938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]